<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412425</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0506</org_study_id>
    <nct_id>NCT00412425</nct_id>
  </id_info>
  <brief_title>Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting</brief_title>
  <official_title>Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        -  Safety of palonosetron administered for control of nausea and vomiting in patients with
           metastatic melanoma receiving biochemotherapy.

        -  To determine the patterns and severity of nausea and vomiting in two groups of patients
           with metastatic melanoma receiving biochemotherapy with palonosetron premedication using
           two schedules of palonosetron administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Palonosetron is designed to work by blocking the substance serotonin from binding to the
      brain and gastrointestinal tract, which may help to decrease nausea and vomiting.

      Participants in this study will be receiving biochemotherapy treatment as part of their
      routine care. This treatment will include 3 chemotherapy drugs (cisplatin, vinblastine, and
      DTIC) and 2 drugs that stimulate the immune system (interferon and interleukin-2 (IL-2)).
      Biochemotherapy often causes nausea, vomiting, loss of appetite, and weight loss.
      Palonosetron will be given on this study to try to treat the side effects of biochemotherapy.

      If you agree to take part in this study, you will be randomly assigned (as in the toss of a
      coin) to one of 2 treatment groups. You have an equal chance of being assigned to either
      group.

      Participants in Group 1 will receive palonosetron by vein over a few minutes starting 30
      minutes before receiving chemotherapy on Days 1 and 4 of therapy. Participants in Group 2
      will receive palonosetron by vein over a few minutes on Days 1, 3, and 5.

      All participants on this study will also receive Ativan by vein every 8 hours for 5 days.
      Ativan is given for additional control of nausea and it will also help to sedate you. In
      addition to palonosetron, you may be given standard anti-nausea medications such as lorazepam
      or compazine if you experience intolerable nausea and vomiting while on study.

      You will also be asked to fill out a Functional Living Index-Emesis (FLIE) questionnaire
      every day for 7 days in a row. The questionnaire will ask about any nausea and/or vomiting
      you are experiencing and the effect of the therapy on your quality of life. You will stay in
      the hospital for at least 7 days while you receive treatment.

      After the first course of palonosetron given with biochemotherapy, your doctor will decide if
      you will receive additional courses of palonosetron or if you will be given another
      anti-nausea drug.

      If your doctor does decide to have you continue on palonosetron, it will be given off study.
      Your participation in this study will be over after 1 course.

      This is an investigational study. Palonosetron has been approved by FDA for control of nausea
      and vomiting caused by chemotherapy. However, it has not been adequately evaluated for safety
      and effectiveness in patients receiving high dose interleukin-2 alone or in combination with
      chemotherapy. About 30 patients will take part in this study. All patients will enrolled at
      M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Participants Response to Palonosetron</measure>
    <time_frame>7 days</time_frame>
    <description>Participants response measured as incidences biochemotherapy emesis and those of nausea interfering with appetite, sleep, physical activity, social life and enjoyment of life are summarized. Response evaluated during 5-day administration of biochemotherapy and the 23 subsequent days after therapy ends.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>2 Days Palonosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 Days Palonosetron 0.25 mg intravenous (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Days Palonosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 Days Palonosetron 0.25 mg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.</description>
    <arm_group_label>2 Days Palonosetron</arm_group_label>
    <arm_group_label>3 Days Palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They have non-resectable stage III or IV metastatic melanoma with measurable disease
             and have agreed to be treated with biochemotherapy.

          -  They have Zubrod performance status of 0-1

          -  They have normal blood counts with a white blood count (WBC) count &gt;/= 3,500/mm^3, ANC
             &gt;/= 1,500/mm^3 and a platelet count &gt;/= 100,000/mm^3 and have serum creatinine &lt;1.5
             mg/dl, and serum bilirubin level &lt; 1.5 mg/dl, and no evidence of significant cardiac
             or pulmonary dysfunction.

          -  They have no significant intercurrent illness such as a serious infection, significant
             psychiatric illness, hypercalcemia (calcium &gt;11 mg), gastro-intestinal (GI) bleeding
             or evidence of brain metastasis.

          -  They have not been exposed to prior interferon, interleukin-2 or previous chemotherapy
             including regional perfusion. Prior radiation therapy for metastatic melanoma is
             permitted provided the patient has unirradiated metastatic sites for response
             evaluation and has fully recovered from its toxicity.

          -  They must have been off corticosteroids for at least 2 weeks.

        Exclusion Criteria:

          -  They are younger than 18 years or more than 65 years of age and those with an expected
             survival of less than 8 weeks or a Zubrod performance status of 2, 3 or 4.

          -  They have received previous treatment with any prior systemic chemotherapy for
             unresectable metastasis including and not limited to the following drugs: cisplatin,
             vinblastine, Dacarbazine (DTIC), interferon and interleukin-2

          -  They have active central nervous system involvement by melanoma either as brain
             metastasis, spinal cord compression, or meningeal carcinomatosis&quot;.

          -  They have significant cardiac illness such as symptomatic coronary artery disease or
             previous history of myocardial infarction, impaired left ventricular function or
             serious cardiac arrhythmias requiring therapy.

          -  They have significant impairment of pulmonary function on account of chronic
             bronchitis or chronic obstructive pulmonary disease (COPD).

          -  They have symptomatic effusions on account of pleural, pericardial or peritoneal
             metastasis of melanoma.

          -  They have history of a second malignant tumor (except for other skin cancers and in
             situ carcinoma of the cervix) within the past 5 years and uncertainty about the
             histologic nature of the metastatic lesions.

          -  They are on corticosteroids or any other type of immunosuppressive agent (e.g.,
             methotrexate, chloroquine, azathioprine, cyclophosphamide).

          -  They are pregnant or breast feeding. Patients of childbearing potential must agree to
             use an effective method of contraception.

          -  They have known hypersensitivity to any of the study drugs or to other selective
             5-HT3(subscript).

          -  They have ongoing emesis due to any organic etiology including but not limited to
             central nervous system or gastrointestinal metastasis.

          -  They have grade 2 or higher nausea due to administration of drugs including but not
             limited to narcotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agop Y. Bedikian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T. M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <results_first_submitted>February 7, 2012</results_first_submitted>
  <results_first_submitted_qc>April 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2012</results_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Palonosetron</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Vinblastine</keyword>
  <keyword>Loss of Appetite</keyword>
  <keyword>Weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 11/17/2006 - 8/1/2008. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>3 Days Palonosetron</title>
          <description>3 Days Palonosetron 0.25 mg intravenous (IV)</description>
        </group>
        <group group_id="P2">
          <title>2 Days Palonosetron</title>
          <description>2 Days Palonosetron 0.25 mg IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 Days Palonosetron</title>
          <description>3 Days Palonosetron 0.25 mg intravenous (IV)</description>
        </group>
        <group group_id="B2">
          <title>2 Days Palonosetron</title>
          <description>2 Days Palonosetron 0.25 mg IV</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="23" upper_limit="64"/>
                    <measurement group_id="B2" value="49" lower_limit="33" upper_limit="65"/>
                    <measurement group_id="B3" value="53" lower_limit="23" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Participants Response to Palonosetron</title>
        <description>Participants response measured as incidences biochemotherapy emesis and those of nausea interfering with appetite, sleep, physical activity, social life and enjoyment of life are summarized. Response evaluated during 5-day administration of biochemotherapy and the 23 subsequent days after therapy ends.</description>
        <time_frame>7 days</time_frame>
        <population>Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>3 Days Palonosetron</title>
            <description>3 Days Palonosetron 0.25 mg intravenous (IV)</description>
          </group>
          <group group_id="O2">
            <title>2 Days Palonosetron</title>
            <description>2 Days Palonosetron 0.25 mg IV</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Participants Response to Palonosetron</title>
          <description>Participants response measured as incidences biochemotherapy emesis and those of nausea interfering with appetite, sleep, physical activity, social life and enjoyment of life are summarized. Response evaluated during 5-day administration of biochemotherapy and the 23 subsequent days after therapy ends.</description>
          <population>Analysis was per protocol.</population>
          <units>episodes of nausea/vomiting</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea Episodes (First 7 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Episodes (First 7 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3 Days Palonosetron</title>
          <description>3 Days Palonosetron 0.25 mg intravenous (IV)</description>
        </group>
        <group group_id="E2">
          <title>2 Days Palonosetron</title>
          <description>2 Days Palonosetron 0.25 mg IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="128" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" events="207" subjects_affected="14" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="57" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" events="89" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Agop Bedikian, MD Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>asreckew@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

